Go Pro
→ Your book attached (From Profits Run) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CG Oncology, Inc. stock logo
CGON
CG Oncology
$79.81
+2.8%		$71.31
$25.25
▼
$80.97
$7.07B0.23784,689 shs701,651 shs
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
$59.50
+2.4%		$53.05
$44.12
▼
$78.48
$5.75B1.741.52 million shs2.45 million shs
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
$107.96
+3.0%		$91.82
$14.34
▼
$115.51
$7.15B-0.34787,185 shs935,783 shs
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
$3.50
+4.8%		$3.30
$2.77
▼
$7.18
$1.87B1.0315.98 million shs22.85 million shs
Don't Wait for the OpenAI IPO Cover
Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CG Oncology, Inc. stock logo
CGON
CG Oncology
0.00%+6.37%+12.22%+24.22%+212.61%
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
0.00%+11.11%+25.18%+18.15%+12.12%
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
0.00%-2.77%+17.41%+78.12%+649.72%
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
0.00%+10.76%+16.28%+16.28%-26.62%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CG Oncology, Inc. stock logo
CGON
CG Oncology
$79.81
+2.8%		$71.31
$25.25
▼
$80.97
$7.07B0.23784,689 shs701,651 shs
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
$59.50
+2.4%		$53.05
$44.12
▼
$78.48
$5.75B1.741.52 million shs2.45 million shs
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
$107.96
+3.0%		$91.82
$14.34
▼
$115.51
$7.15B-0.34787,185 shs935,783 shs
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
$3.50
+4.8%		$3.30
$2.77
▼
$7.18
$1.87B1.0315.98 million shs22.85 million shs
Don't Wait for the OpenAI IPO Cover
Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CG Oncology, Inc. stock logo
CGON
CG Oncology
0.00%+6.37%+12.22%+24.22%+212.61%
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
0.00%+11.11%+25.18%+18.15%+12.12%
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
0.00%-2.77%+17.41%+78.12%+649.72%
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
0.00%+10.76%+16.28%+16.28%-26.62%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
CG Oncology, Inc. stock logo
CGON
CG Oncology
2.71
Moderate Buy$83.184.22% Upside
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
2.58
Moderate Buy$68.0614.38% Upside
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
2.82
Moderate Buy$134.3024.40% Upside
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
2.20
Hold$8.06130.29% Upside

Current Analyst Ratings Breakdown

Latest RXRX, CRSP, ORKA, and CGON Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/17/2026
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$5.30
8/11/2026
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$200.00
8/11/2026
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
Wedbush logo
Wedbush
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform$165.00
8/11/2026
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
BTIG Research logo
BTIG Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$151.00
8/7/2026
CG Oncology, Inc. stock logo
CGON
CG Oncology
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOutperform$81.00 ➝ $79.00
8/7/2026
CG Oncology, Inc. stock logo
CGON
CG Oncology
Piper Sandler logo
Piper Sandler
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$82.00 ➝ $85.00
8/7/2026
CG Oncology, Inc. stock logo
CGON
CG Oncology
Truist Financial Corporation logo
Truist Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$82.00 ➝ $85.00
8/6/2026
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
The Goldman Sachs Group, Inc. logo
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingNeutral$55.00
8/4/2026
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$82.00 ➝ $88.00
8/3/2026
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$120.00
7/29/2026
CG Oncology, Inc. stock logo
CGON
CG Oncology
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$100.00
(Data available from 8/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
CG Oncology, Inc. stock logo
CGON
CG Oncology
$4.04M1,751.08N/AN/A$11.61 per share6.87
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
$3.51M1,639.05N/AN/A$18.06 per share3.29
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
N/AN/AN/AN/A$16.79 per shareN/A
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
$74.68M25.09N/AN/A$1.71 per share2.05
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
CG Oncology, Inc. stock logo
CGON
CG Oncology
-$160.99M-$2.69N/AN/AN/A-3,602.68%-25.20%-23.98%N/A
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
-$581.60M-$4.76N/AN/AN/A-3,368.72%-24.39%-18.25%11/9/2026 (Estimated)
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
-$105.43M-$2.03N/AN/AN/AN/A-21.65%-20.88%11/11/2026 (Estimated)
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
-$644.76M-$1.04N/AN/AN/A-945.94%-50.41%-38.25%11/4/2026 (Estimated)

Latest RXRX, CRSP, ORKA, and CGON Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/10/2026Q2 2026
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
-$0.5125-$0.55-$0.0375-$0.55N/AN/A
8/6/2026Q2 2026
CG Oncology, Inc. stock logo
CGON
CG Oncology
-$0.6642-$0.90-$0.2359-$0.90$0.36 million$1.16 million
8/5/2026Q2 2026
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
-$0.24-$0.25-$0.01-$0.25$10.97 million$7.67 million
8/3/2026Q2 2026
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
-$1.19-$0.94+$0.25-$0.94$7.45 million$10.18 million
6/30/2026Q2 2026
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
N/A-$0.94N/A-$0.94N/A$10.18 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
CG Oncology, Inc. stock logo
CGON
CG Oncology
N/AN/AN/AN/AN/A
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
N/AN/AN/AN/AN/A
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
N/AN/AN/AN/AN/A
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
CG Oncology, Inc. stock logo
CGON
CG Oncology
N/A
22.22
22.20
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
0.34
17.85
17.85
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
N/A
38.51
38.51
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
0.01
5.03
5.03

Institutional Ownership

CompanyInstitutional Ownership
CG Oncology, Inc. stock logo
CGON
CG Oncology
26.56%
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
69.20%
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
56.44%
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
89.06%

Insider Ownership

CompanyInsider Ownership
CG Oncology, Inc. stock logo
CGON
CG Oncology
4.80%
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
5.20%
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
23.49%
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
6.65%
CompanyEmployeesShares OutstandingFree FloatOptionable
CG Oncology, Inc. stock logo
CGON
CG Oncology
6188.64 million84.39 millionOptionable
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
46096.69 million91.67 millionOptionable
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
N/A66.21 million50.66 millionN/A
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
400535.34 million499.74 millionOptionable

Recent News About These Companies

Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Up 9.8% - Still a Buy?
August 19, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/recursion-pharmaceuticals-nasdaqrxrx-shares-up-98-still-a-buy-2026-08-19/
The Zacks Analyst Blog Highlights Recursion Pharmaceuticals, Schrodinger, Relay Therapeutics and Absci
August 18, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/zacks-analyst-blog-highlights-recursion-074300158.html
Contineum, Disc Medicine, Recursion Advance Pipelines Ahead of Catalysts, Morgan Stanley Says
August 17, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/contineum-disc-medicine-recursion-advance-150138340.html
4 AI-Powered Drug Discovery Stocks to Watch as AI Reshapes Pharma
August 17, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2975676/4-ai-powered-drug-discovery-stocks-to-watch-as-ai-reshapes-pharma?cid=cs-stocknewsapi-ft-analyst_blog|investment_ideas-2975676
Recursion Pharmaceuticals Highlights AI Platform, Roche Progress and Pipeline Updates
August 17, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/recursion-pharmaceuticals-highlights-ai-platform-roche-progress-and-pipeline-updates-2026-08-17/
Recursion (RXRX) Q2 2026 Earnings Call Transcript
August 12, 2026  |  fool.comhttps://www.fool.com/earnings/call-transcripts/2026/08/12/recursion-rxrx-q2-2026-earnings-call-transcript/
Recursion Pharmaceuticals, Inc. (RXRX) Presents at Bank of America SMID Cap Virtual Conference Transcript
August 11, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4934810-recursion-pharmaceuticals-inc-rxrx-presents-at-bank-of-america-smid-cap-virtual-conference
Stock Traders Purchase High Volume of Put Options on Recursion Pharmaceuticals (NASDAQ:RXRX)
August 11, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/stock-traders-purchase-high-volume-of-put-options-on-recursion-pharmaceuticals-nasdaqrxrx-2026-08-11/
The Biggest IPO of the Year Is Targeted in the Next 60 Days. Why One Unexpected Industry Could Rally Before Then (Hint: It’s Not Tech)
August 11, 2026  |  247wallst.comhttps://247wallst.com/investing/2026/08/11/the-biggest-ipo-of-the-year-is-targeted-in-the-next-60-days-why-one-unexpected-industry-could-rally-before-then-its-not-tech/
Recursion Pharmaceuticals: I'm Still Bearish Despite Recent Genentech News
August 10, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4934323-recursion-pharmaceuticals-im-still-bearish-despite-recent-genentech-news
TD Cowen Keeps Their Hold Rating on Recursion Pharmaceuticals (RXRX)
August 9, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/RXRX/pressreleases/3714554/td-cowen-keeps-their-hold-rating-on-recursion-pharmaceuticals-rxrx/
Recursion Pharmaceuticals, Inc. 2026 Q2 - Results - Earnings Call Presentation
August 9, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4933927-recursion-pharmaceuticals-inc-2026-q2-results-earnings-call-presentation
Recursion Pharmaceuticals (NASDAQ:RXRX) Cut to "Strong Sell" at Wall Street Zen
August 8, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/recursion-pharmaceuticals-nasdaqrxrx-cut-to-strong-sell-at-wall-street-zen-2026-08-08/
Recursion Pharmaceuticals (NASDAQ:RXRX) Director Blake Borgeson Sells 30,000 Shares of Stock
August 7, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-rxrx-insider-buying-and-selling-2026-08-07/
Blake Borgeson Sells 30,000 Shares of Recursion Pharmaceuticals (NASDAQ:RXRX) Stock
August 6, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/blake-borgeson-sells-30000-shares-of-recursion-pharmaceuticals-nasdaqrxrx-stock-2026-08-06/
RXRX Q2 Earnings Miss Estimates, Revenues Fall Y/Y, Stock Down
August 6, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2970097/rxrx-q2-earnings-miss-estimates-revenues-fall-y-y-stock-down?cid=cs-stocknewsapi-ft-analyst_blog|earnings_article-2970097
Recursion Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary
August 6, 2026  |  app.moby.coA
Bank of New York Mellon Corp Boosts Stake in Recursion Pharmaceuticals, Inc. $RXRX
August 6, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-bank-of-new-york-mellon-corp-boosts-stake-in-recursion-pharmaceuticals-inc-rxrx-2026-08-06/
Recursion outlines $375M 2026 cash OpEx guidance while advancing first Genentech neuroscience target
August 5, 2026  |  seekingalpha.comhttps://seekingalpha.com/news/4626363-recursion-outlines-375m-2026-cash-opex-guidance-while-advancing-first-genentech-neuroscience
Recursion Pharmaceuticals (NASDAQ:RXRX) Releases Earnings Results, Misses Estimates By $0.01 EPS
August 5, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/recursion-pharmaceuticals-nasdaqrxrx-releases-earnings-results-misses-estimates-by-001-eps-2026-08-05/
Recursion Pharmaceuticals Q2 Earnings Call Highlights
August 5, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/recursion-pharmaceuticals-q2-earnings-call-highlights-2026-08-05/

New MarketBeat Followers Over Time

Media Sentiment Over Time

CG Oncology stock logo

CG Oncology NASDAQ:CGON

$79.81 +2.20 (+2.83%)
As of 08/21/2026 04:00 PM Eastern

CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.

CRISPR Therapeutics stock logo

CRISPR Therapeutics NASDAQ:CRSP

$59.50 +1.38 (+2.37%)
As of 08/21/2026 04:00 PM Eastern

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.

Oruka Therapeutics stock logo

Oruka Therapeutics NASDAQ:ORKA

$107.96 +3.10 (+2.96%)
As of 08/21/2026 04:00 PM Eastern

Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.

Recursion Pharmaceuticals stock logo

Recursion Pharmaceuticals NASDAQ:RXRX

$3.50 +0.16 (+4.79%)
As of 08/21/2026 04:00 PM Eastern

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas